At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 36 enrolled
Drug / intervention
exemestane +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intermittent Exemestane Therapy for Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating exemestane, laboratory biomarker analysis, and 2 other interventions for Breast Cancer. Completed, enrolled 36 participants across 2 sites.
Detailed Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well exemestane works in treating postmenopausal women with stage IV breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionJun 2019
TodayJul 2026
First PostedDec 18, 2008
Enrollment StartDec 2, 2008
Primary CompletionJun 26, 2019
TodayJul 2, 2026
Enrollment to primary: 10.6 yearsPosted 17.5 years ago
Interventions
exemestanedrug
Given orally
laboratory biomarker analysisother
One year after completion of study treatment
quality-of-life assessmentprocedure
One year after completion of study treatment
immunohistochemistry staining methodother
Correlative studies